Ace­sion clinch­es $47M in Se­ries B raise to ad­vance pre­clin­i­cal car­diac ar­rhyth­mia can­di­date through PhII

Ace­sion Phar­ma has bagged 45 mil­lion eu­ros ($47 mil­lion) in an over­sub­scribed Se­ries B round. The fund­ing will sup­port its pre­clin­i­cal oral potas­si­um chan­nel in­hibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER